According to the latest report published by Credence Research, Inc. “Diabetes Drugs Market – Growth, Future Prospects and Competitive Analysis, 2017-2025,” the global diabetes drugs market was valued at US$ 49.26 Bn in 2016.
The purpose of the report is to illustrate the state of the market of Diabetes Drugs, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report: https://www.credenceresearch.com/report/diabetes-drugs-market
Diabetes mellitus, often referred as diabetes is one of the largest global health extremities of the 21st century. It is a serious prolonged disease that arises either when pancreas does not secrete sufficient insulin (a hormone that regulates glucose, or blood sugar), or when the body cannot efficiently utilize the insulin it secretes. According to the International Diabetes Federation, approximately 415 million adults currently have diabetes, and by 2040 this pool will rise to 642 million. Due to population growth, unhealthy diets, obesity, aging and sedentary lifestyle, there may be an increase in number of cases in emerging countries. The primary driving force of the global diabetes drugs market is the growing prevalence of diabetes, both the number of cases and prevalence have been progressively increasing over the past few decades. Trend in the growth rate of the population of older persons also reveals the powerful influence on diabetes drugs market.
The market is mainly expected to be driven by large patient pool suffering from diabetes, more R&D in diabetes diagnosis and treatment, minimally or non-invasive products, and improving diagnosis and treatment rates. Moreover, it is observed that growing middle class population, changing demographic profiles, increase in number of consumers with medical insurance, expanding economy, and increasing per capita GDP are also expected to provide massive opportunities for diabetes drugs manufacturers all over the world and especially in Asia Pacific (APAC) region. The global diabetes drugs market is categorized into the insulin, oral hypoglycemic drugs (anti-diabetes drugs), non-insulin injectable anti-diabetes drugs and others. All drugs are delivered orally except exenatide, insulin, liraglutide, and paramlintide.
Geographically, the global diabetes drugs market is studied for Asia Pacific, Europe, North America, Latin America and Middle East and Africa. In terms of revenue share North America lead the global market and it is anticipated that the region will retain its supremacy during the forecast period. However, the dominance of North America will be prominently challenged by Asia Pacific market due to increase in geriatric population and rising prevalence of diabetes in developing countries like China and India. The global diabetes drugs market is driven primarily by the expanding diabetic population around the world. The Asia Pacific will occupy the more market share in following years. Furthermore, countries such as China also fast growing India and Southeast Asia region will open additional opportunities for market penetration to key companies already having a grip in developed regions.
2.1. Global Diabetes Drugs Market Portraiture
2.1.1. Global Diabetes Drugs Market, by Type of Therapy, 2016 (US$ Bn)
2.1.2. Global Diabetes Drugs Market, by Geography, 2016 (US$ Bn)
Chapter 3. Diabetes Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Diabetes: Epidemiology
3.5.1. Attractive Investment Proposition, by Geography, 2016
3.6. Value Chain Analysis
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Diabetes Drugs Market, by Type of Therapy, 2015 – 2025 (US$ Bn)
4.2. Attractive Investment Proposition, by Type of Therapy, 2016
4.4. Oral Hypoglycemic Drugs (anti-diabetes drugs)
4.5. Non-insulin Injectable Anti-diabetes Drugs
4.7. Phase III (Market estimations by 2025)
4.7.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
4.7.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
4.7.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
4.8. Tabular Presentation of Phase II (Qualitative Information)
4.9. Tabular Presentation of Phase Phase I (Qualitative Information)
6.1.1. AstraZeneca plc
6.1.2. Business Description
6.1.3. Financial Information (Subject to data availability)
6.1.4. Application Portfolio
6.1.5. Key Developments
6.2. Biocon Limited
6.3. Boston Therapeutics, Inc.
6.4. Cadila Healthcare
6.5. Eli Lilly and Company
6.6. GlaxoSmithKline plc
6.7. Johnson & Johnson
6.8. Lupin Limited
6.9. Merck & Co., Inc.
6.10. Novartis International AG
6.11. Pfizer Inc.
6.12. Ranbaxy Laboratories Limited
6.13. Sanofi S.A.
6.14. Takeda Pharmaceutical Company Ltd.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Diabetes Drugs buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Diabetes Drugs contains:
Analysis and forecast of Diabetes Drugs market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Diabetes Drugs market;
Assessment and forecast of Diabetes Drugs market development;
Financial and business profiles of the leading companies in the Diabetes Drugs industry.
– Up to date working Diabetes Drugs data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Diabetes Drugs for the period 2018 to 2026
– Planned Diabetes Drugs additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Diabetes Drugs projects by region, key countries, and companies
– Details of major planned Diabetes Drugs projects in the world up to 2026
Also you can request us for sample in pdf with more details and graph: https://www.credenceresearch.com/sample-request/58812
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290